Perioperative durvalumab has “the potential to transform the standard of care” for patients with muscle-invasive bladder ...

Adjuvant durvalumab did not improve disease-free survival in patients with early-stage non-small cell lung cancer in the phase 3 BR.31 trial.

Recent advances in bladder cancer treatments may offer hope of curative care to more patients, including those with high-risk ...

AstraZeneca’s growth was driven by its portfolio of products in the oncology, biopharmaceuticals and rare disease segments ...

NKTR-255 in combination with durvalumab following chemoradiation was well-tolerated in patients with non–small cell lung ...

The top stories in non-small cell lung cancer (NSCLC) for 2024 included practice-changing results in EGFR-mutant disease, an ...

AstraZeneca has become the latest big pharma company to devote new cash to its US manufacturing muscle this year as it ...

In a move aimed at providing relief to cancer patients, the National Pharmaceutical Pricing Authority (NPPA) has directed ...

Lung cancer is diagnosed by taking a biopsy from the suspicious area of the lung, which can be done with both bronchoscopy ...

The 22nd Annual Winter Lung Cancer Conference, January 31-February 2, 2025, will cover advances in NSCLC and SCLC treatment.